Virax Biolabs Confirms Exercise of Pre-Funded Warrants, Resulting in Significant Share Dilution
VRAX sits 72% above its 52-week low of $0.1 on elevated volume (6.1× avg).
Summary
Virax Biolabs announced the full exercise of 12.5 million pre-funded warrants from a December 2025 private placement, increasing outstanding shares and confirming significant dilution.
Key Events · Financing and Capital Events · VRAX
-
Pre-Funded Warrants Fully Exercised
All 12,500,000 pre-funded warrants from the December 2025 private placement have been exercised as of April 10, 2026.
-
Significant Share Dilution Confirmed
The exercise of these warrants has increased the total ordinary shares outstanding to 19,923,432, representing substantial dilution for existing shareholders.
-
Remaining Preferred Options
An additional 12,500,000 preferred investment options remain outstanding, exercisable at $0.40 per share, which would result in further dilution if exercised. These options are currently out-of-the-money compared to the current stock price of $0.172.
Analysis · VRAX · Life Sciences
This 6-K filing provides a material update to a previously reported private placement from December 2025. It confirms the full exercise of 12.5 million pre-funded warrants, significantly increasing the company's outstanding share count to 19,923,432. While the original private placement provided $5 million in gross proceeds, this exercise represents substantial dilution for existing shareholders. Additionally, 12.5 million preferred investment options remain outstanding, which, if exercised, would lead to further significant dilution, though they are currently out-of-the-money.
At the time of this filing, VRAX was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $772.8K. The 52-week trading range was $0.10 to $1.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.